128 related articles for article (PubMed ID: 14604812)
1. The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy.
Chegini N; Luo X; Ding L; Ripley D
Mol Cell Endocrinol; 2003 Nov; 209(1-2):9-16. PubMed ID: 14604812
[TBL] [Abstract][Full Text] [Related]
2. Differential expression, regulation, and induction of Smads, transforming growth factor-beta signal transduction pathway in leiomyoma, and myometrial smooth muscle cells and alteration by gonadotropin-releasing hormone analog.
Xu J; Luo X; Chegini N
J Clin Endocrinol Metab; 2003 Mar; 88(3):1350-61. PubMed ID: 12629129
[TBL] [Abstract][Full Text] [Related]
3. Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-beta through Smad and MAPK-mediated signalling.
Levens E; Luo X; Ding L; Williams RS; Chegini N
Mol Hum Reprod; 2005 Jul; 11(7):489-94. PubMed ID: 16123076
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells.
Luo X; Xu J; Chegini N
Reprod Biol Endocrinol; 2003 Dec; 1():125. PubMed ID: 14678567
[TBL] [Abstract][Full Text] [Related]
5. CCNs, fibulin-1C and S100A4 expression in leiomyoma and myometrium: inverse association with TGF-beta and regulation by TGF-beta in leiomyoma and myometrial smooth muscle cells.
Luo X; Ding L; Chegini N
Mol Hum Reprod; 2006 Apr; 12(4):245-56. PubMed ID: 16571622
[TBL] [Abstract][Full Text] [Related]
6. Leiomyoma and myometrial gene expression profiles and their responses to gonadotropin-releasing hormone analog therapy.
Luo X; Ding L; Xu J; Williams RS; Chegini N
Endocrinology; 2005 Mar; 146(3):1074-96. PubMed ID: 15604208
[TBL] [Abstract][Full Text] [Related]
7. The expression of Abl interactor 2 in leiomyoma and myometrium and regulation by GnRH analogue and transforming growth factor-beta.
Luo X; Levens E; Williams RS; Chegini N
Hum Reprod; 2006 Jun; 21(6):1380-6. PubMed ID: 16488906
[TBL] [Abstract][Full Text] [Related]
8. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy.
Dou Q; Zhao Y; Tarnuzzer RW; Rong H; Williams RS; Schultz GS; Chegini N
J Clin Endocrinol Metab; 1996 Sep; 81(9):3222-30. PubMed ID: 8784073
[TBL] [Abstract][Full Text] [Related]
9. The expression of Smads in human endometrium and regulation and induction in endometrial epithelial and stromal cells by transforming growth factor-beta.
Luo X; Xu J; Chegini N
J Clin Endocrinol Metab; 2003 Oct; 88(10):4967-76. PubMed ID: 14557482
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma.
Chegini N; Kornberg L
J Soc Gynecol Investig; 2003 Jan; 10(1):21-6. PubMed ID: 12517589
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells.
Ding L; Xu J; Luo X; Chegini N
J Clin Endocrinol Metab; 2004 Nov; 89(11):5549-57. PubMed ID: 15531510
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy.
Chegini N; Verala J; Luo X; Xu J; Williams RS
J Soc Gynecol Investig; 2003 Apr; 10(3):161-71. PubMed ID: 12699880
[TBL] [Abstract][Full Text] [Related]
13. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor.
Kuratomi G; Komuro A; Goto K; Shinozaki M; Miyazawa K; Miyazono K; Imamura T
Biochem J; 2005 Mar; 386(Pt 3):461-70. PubMed ID: 15496141
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro.
Chegini N; Rong H; Dou Q; Kipersztok S; Williams RS
J Clin Endocrinol Metab; 1996 Sep; 81(9):3215-21. PubMed ID: 8784072
[TBL] [Abstract][Full Text] [Related]
15. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor.
De Falco M; Staibano S; D'Armiento FP; Mascolo M; Salvatore G; Busiello A; Carbone IF; Pollio F; Di Lieto A
J Soc Gynecol Investig; 2006 May; 13(4):297-303. PubMed ID: 16697947
[TBL] [Abstract][Full Text] [Related]
16. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
Poncelet AC; de Caestecker MP; Schnaper HW
Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
[TBL] [Abstract][Full Text] [Related]
17. Deficient Smad7 expression: a putative molecular defect in scleroderma.
Dong C; Zhu S; Wang T; Yoon W; Li Z; Alvarez RJ; ten Dijke P; White B; Wigley FM; Goldschmidt-Clermont PJ
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3908-13. PubMed ID: 11904440
[TBL] [Abstract][Full Text] [Related]
18. Localization of Smads, the TGF-beta family intracellular signaling components during endochondral ossification.
Sakou T; Onishi T; Yamamoto T; Nagamine T; Sampath Tk; Ten Dijke P
J Bone Miner Res; 1999 Jul; 14(7):1145-52. PubMed ID: 10404014
[TBL] [Abstract][Full Text] [Related]
19. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta.
Lee BS; Nowak RA
J Clin Endocrinol Metab; 2001 Feb; 86(2):913-20. PubMed ID: 11158066
[TBL] [Abstract][Full Text] [Related]
20. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
